Association between AMPD1 gene polymorphism and coagulation factors in patients with coronary heart disease

Pathophysiology of Haemostasis and Thrombosis

Volumn 35, Issue 6, 2006, Pages 440-444

  Agewall, S ^a,b   Norman, B ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b AKER UNIVERSITY HOSPITAL   (Norway)

Author keywords

AMPD1; Atherosclerosis; Flow mediated dilatation; Intima media thickness; Left ventricular hypertrophy; Myocardial infarction; PAI 1 activity; Von Willebrand factor

Indexed keywords

ADENOSINE MONOPHOSPHATE DEAMINASE; ADENOSINE MONOPHOSPHATE DEAMINASE 1; GLUCOSE; PLASMINOGEN ACTIVATOR INHIBITOR 1; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BRACHIAL ARTERY; CARDIOVASCULAR RISK; CAROTID ARTERY; CONTROLLED STUDY; DNA POLYMORPHISM; FEMALE; GENE CASSETTE; GLUCOSE METABOLISM; HEART EJECTION FRACTION; HEART VENTRICLE HYPERTROPHY; HEMOSTASIS; HOMOZYGOTE; HUMAN; INTIMA; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; VASCULAR ENDOTHELIUM;

ADULT; AGED; AGED, 80 AND OVER; ALLELES; AMINO ACID SUBSTITUTION; AMP DEAMINASE; CARDIOMEGALY; CAROTID ARTERIES; CORONARY ARTERY DISEASE; FEMALE; GLUCOSE; HETEROZYGOTE; HOMOZYGOTE; HUMANS; MALE; MIDDLE AGED; MUTATION, MISSENSE; PLASMINOGEN ACTIVATOR INHIBITOR 1; POLYMORPHISM, SINGLE NUCLEOTIDE; RISK FACTORS; TUNICA INTIMA; VON WILLEBRAND FACTOR;

EID: 34250220640     PISSN: 14248832     EISSN: None     Source Type: Journal    
DOI: 10.1159/000102051     Document Type: Article

References (29)

1. Norman B, Glenmark B, Jansson E: Muscle AMP deaminase deficiency in 2% of a healthy population. Muscle Nerve 1995;18:239-241.
2. Verzijl HT, van Engelen BG, Luyten JA, Steenbergen GC, van den Heuvel LP, ter Laak HJ, Padberg GW, Wevers RA: Genetic characteristics of myoadenylate deaminase deficiency. Ann Neurol 1998;44:140-143.
3. Morisaki T, Gross M, Morisaki H, Pongratz D, Zollner N, Holmes EW: Molecular basis of AMP deaminase deficiency in skeletal muscle. Proc Natl Acad Sci USA 1992;89:6457-6461.
4. Gross M: New method for detection of C34-T mutation in the AMPD1 gene causing myoadenylate deaminase deficiency. Ann Rheum Dis 1994;53:353-354.
5. Sabina RL, Swain JL, Olanow CW, Bradley WG, Fishbein WN, DiMauro S: Myoadenylate deaminase deficiency: functional and metabolic abnormalities associated with disruption of the purine nucleotide cycle. J Clin Invest 1984;73:720-730.
6. Norman B, Sabina RL, Jansson E: Regulation of skeletal muscle ATP catabolism by AMPD1 genotype during sprint exercise in asymptomatic subjects. J Appl Physiol 2001;91:258-264.
7. Loh E, Rebbeck TR, Mahoney PD, DeNofrio D, Swain JL, Holmes EW: Common variant in AMPD1 gene predicts improved clinical outcome in patients with heart failure. Circulation 1999;99:1422-1425.
8. Gastmann A, Sigusch HH, Henke A, Reinhardt D, Surber R, Gastmann O: Role of adenosine monophosphate deaminase-1 gene polymorphism in patients with congestive heart failure (influence on tumor necrosis factor-α level and outcome). Am J Cardiol 2004;93:1260-1264.
9. Yazaki Y, Muhlestein JB, Carlquist JF, Bair TL, Horne BD, Renlund DG: A common variant of the AMPD1 gene predicts improved survival in patients with ischemic left ventricular dysfunction. J Card Fail 2004;10:316-320.
10. Anderson JL, Habashi J, Carlquist JF, Muhlestein JB, Horne BD, Bair TL: A common variant of the AMPD1 gene predicts improved cardiovascular survival in patients with coronary artery disease. J Am Coll Cardiol 2000;36:1248-1252.
11. Leesar MA, Stoddard M, Ahmed M, Broadbent J, Bolli R: Preconditioning of human myocardium with adenosine during coronary angioplasty. Circulation 1997;95:2500-2507.
12. Pomerantz BJ, Joo K, Shames BD, Cleveland JC, Banerjee A, Harken AH: Adenosine preconditioning reduces both pre and postischemic arrhythmia in human myocardium. J Surg Res 2000;90:191-196.
13. Alpert JS, Thygesen K, Antman E, Bassand JP: Myocardial infarction redefined - a consensus document of The Joint European Society of Cardiology/American College of Cardiology Committee for the redefinition of myocardial infarction. J Am Coll Cardiol 2000;36:959-969.
14. Chenillot O, Henny J, Steinmetz J: High sensitivity C-reactive protein: biological variations and reference limits. Clin Chem Lab Med 2000;038:1003-1011.
15. Alberti KG, Zimmet PZ: Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1. Diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med 1998;15:539-553.
16. Wendelhag I, Liang Q, Gustavsson T, Wikstrand J: A new automated computerized analyzing system simplifies readings and reduces the variability in ultrasound measurement of intima-media thickness. Stroke 1997;28:2195-2200.
17. Jogestrand T, Nowak J, Sylvén C: Improvement of common carotid intima-media complex measurements by calculating the crosssectional area. J Vasc Invest 1995;4:193-195.
18. Nowak J, Nilsson T, Sylven C, Jogestrand T: Potential of carotid ultrasonography in the diagnosis of coronary artery disease: a comparison with exercise test and variance ECG. Stroke 1998;29:439-446.
19. Corretti MC, Anderson TJ, Benjamin EJ, Celermajer D, Charbonneau F, Creager MA; International Brachial Artery Reactivity Task Force: Guidelines for the ultrasound assessment of endothelial-dependent flow-mediated vasodilation of the brachial artery: a report of the International Brachial Artery Reactivity Task Force. J Am Coll Cardiol 2002;39:257-265.
20. Rohani M, Agewall S: Oral snuff impairs endothelial function in healthy snuff users. J Intern Med. 2004;255:379-383.
21. Schiller NB, Shah PM, Crawford M, DeMaria A, Devereux R, Feigenbaum H: Recommendations for quantitation of the left ventricle by two-dimensional echocardiography. American Society of Echocardiography Committee on Standards, Subcommittee on Quantitation of Two-Dimensional Echocardiograms. J Am Soc Echocardiogr 1989;2:358-367.
22. Owen A: Effect of increasing age on diastolic motion of the left ventricular atrioventricular plane in normal subjects. Int J Cardiol 1999;69:127-132.
23. Dubey RK, Gillispie DG, Mi Z, Jackson EK: Exogenous and endogenous adenosine inhibits fetal calf serum-induced growth of rat cardiac fibroblasts: role of A2B receptors. Circulation 1997;96:2656-2666.
24. Rumley A, Lowe GDO, Sweetnam PM, Yarnell JWG, Ford RP: Factor VIII, von Willebrand Factor and the risk of major ischaemic heart disease in the Caerphilly Heart study. Br J Haematol 1999;105:110-116.
25. Jager A, van Hinsbergh VWM, Kostense PJ, Emeis JJ, Yudkin JS, Nijpels G: Von Willebrand factor, C-reactive protein, and 5-year mortality in diabetic and non-diabetic subjects. The Hoorn Study. Arterioscler Thromb Vasc Biol 1999;19:3071-3078.
26. Juhan-Vague I. Pyke SDM, Alessi MC, Jespersen J, Haverkate F, Thompson SG: Fibrinolytic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. Circulation 1996;94:2057-2063.
27. Hegeman RJ, Eijnden-Schrauwen Y, Emeis JJ: Adenosine 3′:5′- cyclic monophosphate induces regulated secretion of tissue-type plasminogen activator and von Willebrand factor from cultured human endothelial cells. Thromb Haemost 1998;79:853-858.
28. Kohler HP, Grant PJ: Plasminogen-activator inhibitor type 1 and coronary artery disease. N Engl J Med 2000;342:1792-1801.
29. Lijnen HR: Pleiotropic functions of plasminogen activator inhibitor-1. J Thromb Haemost 2005;3:35-45.